Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matthieu Delaye1, Eric Assenat2, Emmanuel Boleslawski3

  • 1Institut Curie, département d'oncologie médicale. Université Versailles-Saint-Quentin (UVSQ). Saint-Cloud, France; Association pour l'étude des Cancers et Affections des voies Biliaires (ACABi).

Bulletin Du Cancer
|December 19, 2022
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.

medRxiv : the preprint server for health sciences·2026
Same author

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.

NPJ precision oncology·2026
Same author

Improving cancer care while reducing its carbon footprint: GHG-mitigating strategies highlighted at ESMO 2025.

BJC reports·2026
Same author

Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness.

Trends in cancer·2026
Same author

Identifying Predictors of Failure-to-Rescue after Liver Transplantation: A Multicenter Analysis of 1341 Patients.

Clinical transplantation·2026
Same author

Exercise as supportive care in advanced cancer-related weight loss: a feasibility study comparing patients with and without severe weight loss.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles
Summary
This summary is machine-generated.

This survey reveals that while French biliary tract cancer (BTC) treatment often follows standards like capecitabine and cisplatin/gemcitabine, significant practice variations exist between comprehensive cancer centers and general hospitals, impacting care delivery and molecular profiling accessibility.

Area of Science:

  • Oncology
  • Gastroenterology
  • Epidemiology

Context:

  • Biliary tract cancers (BTC) are rare but aggressive malignancies.
  • Management practices for BTC have been evolving, necessitating updated assessments.
  • The ACABi national survey aimed to capture current BTC management in France.

Purpose:

  • To evaluate current biliary tract cancer (BTC) management practices across different healthcare settings in France.
  • To identify variations in diagnostic procedures, adjuvant therapy, first-line and second-line chemotherapy, and molecular profiling.
  • To compare practices between university hospitals/comprehensive cancer centers and general/private hospitals.

Summary:

  • 172 French physicians participated, reporting on BTC management. Capecitabine was common for adjuvant therapy, and cisplatin/gemcitabine (CISGEM) was the preferred first-line chemotherapy for non-operable tumors.
Keywords:
Biliary tract cancersCISGEMDiagnostic moléculaireMolecular profilingPractice assessmentTumeurs des voiesbiliairesdes pratiquesÉvaluation

Related Experiment Videos

  • Significant differences were observed in cholangioscopy availability and molecular profiling rates between comprehensive cancer centers and general hospitals.
  • Practices diverged from recommendations in areas like day hospital chemotherapy administration and treatment breaks.

    • Impact:

    • Highlights adherence to established therapeutic standards in BTC management.
    • Reveals disparities in advanced diagnostic tools and molecular profiling between different types of French healthcare centers.
    • Identifies areas for improvement in BTC care delivery, aiming to standardize treatment and enhance patient outcomes across France.